Navigation Links
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Date:10/15/2007

ANN ARBOR, Mich., Oct. 15 /PRNewswire/ -- Velcura Therapeutics, Inc. has named Jeffrey N. Fellows, a biotechnology regulatory executive with more than 20 years of successful regulatory experience, as Vice President of Regulatory Affairs.

Velcura Therapeutics President and CEO Michael W. Long, PhD, said, "Jeff is a great addition to our senior management team. He will be responsible for our clinical trials applications, regulatory compliance and interactions with the Federal Drug Administration. His more than two decades of experience will be critical in helping Velcura navigate the regulatory path for VEL-0230, our new drug that stimulates bone formation and inhibits bone loss." Dr. Long added, "Jeff's past experience with the Oncology Division at FDA is a definite plus as our initial clinical trial of VEL-0230 in patients will be for treatment for Multiple Myeloma Bone Disease, a blood cancer associated with profound bone loss."

Immediately before joining Velcura Therapeutics, Fellows was Vice President of Regulatory Affairs for Cell Therapeutics, Inc. in Seattle, where for the past three years he was the main liaison with the FDA and responsible for the development of global regulatory strategy and agency filings for the oncology focused company.

Prior to CTI, Fellows worked for Amgen Inc. in Thousand Oaks, CA, and worked in a series of increasingly responsible positions, eventually serving as Director of Regulatory Affairs and Global Regulatory Team Leader in Thousand Oaks, California. There Fellows served on Corporate Global Product Strategy Teams for early- and late-stage development compounds and led Global Regulatory Teams in the United States, Europe, Canada, Australia, and Japan.

After graduation from Oregon State University with a Bachelor of Science in Microbiology, Fellows began his career in regulatory affairs at NeoRx Corporation, where he prepared Investigational New Drug Applications for anti- cancer products. He worked for Synergen, Inc. in Boulder, Colorado, from 1990 until Amgen purchased Synergen in late 1994.

Jeffery Fellows lives in Woodway, Washington, and will work from Velcura's Seattle office.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics, Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. , ... Database technology, today announced the availability of AllegroGraph 6, the leading Semantic Graph ... Cloudera Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph Database ...
(Date:2/8/2016)... February 8, 2016 ... or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, ... its Chlamydia trachomatis (CT) test to be launched on the ... Directive (98/79/EC), the CT test is now cleared for sale ... --> The launch of the io® CT test signals ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical industry ... a host of launch activities including the identification and ... launch activity is especially high in the oncology therapeutic ... Best Practices and the Role of Medical Affairs in ... focused on oncology therapies find better ways to utilize ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... talent development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced sampling of S1423, its ... wearables and small screen applications including smartwatches, fitness ... Supporting round and rectangular shapes, as well as ... performance with moisture on screen, while wearing gloves, ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
Breaking Biology News(10 mins):